Welcome!

We Have the Meningitis Vaccine

Posted: October 4th, 2012 | Author: | Filed under: Passport Health Sarasota-Bradenton Announcements, Travel Health Alerts | Tags: , , , , | Comments Off on We Have the Meningitis Vaccine

An outbreak of Meningitis, a disease that causes inflammation of the meninges, the membranes around the spinal cord and brain, has spread to five states with four dead as of Wednesday October 3, 2012.

The disease has affected patients in Tennessee, Virginia, Maryland, North Carolina and Florida, according to the CDC.  Four people have died as a result of the disease; two in Tennessee and one each in Virginia and Maryland.

Meningitis is a vaccine-preventable disease and Passport Health of Sarasota-Bradenton has the meningococcal vaccine.  We urge residents of the Sarasota-Bradenton area to take proactive action to defend their health!  Why would you wait until you had contracted the disease when it is preventable in the first place?

Call to schedule an appointment (941) 362-0304 or come in to one of our offices.

  • Sarasota Office: 2195 Ringling Blvd, Sarasota, FL 34237
  • Bradenton Office: 4800 26th St West, Bradenton FL 34207

Related articles


Vaccine Company Fights Antitrust Allegations

Posted: September 13th, 2012 | Author: | Filed under: Passport Health Sarasota-Bradenton Announcements | Tags: , , , , , | Comments Off on Vaccine Company Fights Antitrust Allegations

Sanofi Pasteur may find itself in the thick of an antitrust case after a judge ruled that a lawsuit alleging that the company illegally monopolized the market for meningococcal vaccines in theU.S. can move forward.

Sanofi

Sanofi (Photo credit: Wikipedia)

In December, several doctors said the company created a “web of noncompetitive contracts” with physician buying groups that blocked competition in an effort to sell its vaccine MenactraPharmalot reports. Using its market authority, Sanofi grouped price contracts, forcing purchasers to buy 90% or more of childhood vaccines to avoid potential cost penalties on Menactra, according to the news service. So, in theory, a buyer could end up paying 15% to 35% more for all Sanofi vaccines if they elect not to buy Menactra. The doctors surmise Sanofi’s idea here was to promote its Menactra vaccine after Novartis ($NVS) joined the game with rival Menveo.

Furthermore, the lawsuit says the doctors were told, under contract, not to purchase vaccines from other makers–such as GlaxoSmithKline ($GSK) and Novartis–or they would face penalties.

A Sanofi Pasteur spokesman wrote to Pharmalot, “naturally we are disappointed in the judge’s ruling, but we are confident that once the court sees the evidence of competition in the marketplace, it will rule against the plaintiffs. We continue to defend our company and our product, and we maintain that allegations in the class action complaint are without merit.”